M. Erwin

发表

Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Journal of chemotherapy.

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.

R. Jones, H. Sader, M. Erwin, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States

Ronald N. Jones, M. Pfaller, G. Doern, 1998 .

Multicenter Evaluation of the In Vitro Activity of Six Broad-Spectrum β-Lactam Antimicrobial Agents in Puerto Rico

Ronald N. Jones, M. Pfaller, G. Doern, 1998 .

Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis.

R. Jones, H. Sader, B. Runyon, 1995, Diagnostic microbiology and infectious disease.

Emergence of cefepime-resistance in Klebsiella oxytoca clinical isolate due to alteration in the outer membrane permeability

Ronald N. Jones, M. Tuohy, A. Gales, 2000 .

Interpretive criteria for DU-6859a disk diffusion tests using 5-μg disks

Ronald N. Jones, David M. Johnson, M. Erwin, 1994 .

In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 16.5%) application

Ronald N. Jones, M. Bale, D. Hoban, 1993 .

Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.

R. Jones, M. Erwin, S. P. Murphy, 1994, Diagnostic microbiology and infectious disease.

Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.

M. Pfaller, R. Jones, D. M. Johnson, 1999, Diagnostic microbiology and infectious disease.

Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.

J. Hindler, G. Doern, R. Jones, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.

P. Murray, R. Jones, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae.

R. Jones, M. Erwin, M. Barrett, 1993, Diagnostic microbiology and infectious disease.

Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-μg disks

Ronald N. Jones, M. Erwin, M. Barrett, 1992 .

Antimicrobial Activity of Gatifloxacin Against Campylobacter jejuni and Anaerobic Bacteria

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

Gatifloxacin Susceptibility Testing Interpretive Criteria and Quality Control Guidelines for Dilution and Disk Diffusion Methods

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

Antistreptococcal Activity of Gatifloxacin

Ronald N. Jones, D. Biedenbach, M. Beach, 1999, Drugs.

In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application.

R. Jones, M. Bale, D. Hoban, 1993, Diagnostic microbiology and infectious disease.

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, M. Pfaller, G. Doern, 1998, Diagnostic microbiology and infectious disease.

Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.

R. Wenzel, M. Edmond, M. Pfaller, 1997, Diagnostic microbiology and infectious disease.

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.

R. Jones, M. Erwin, M. Erwin, 1995, Diagnostic microbiology and infectious disease.

New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.

R. Jones, M. Bale, M. Erwin, 1992, Diagnostic microbiology and infectious disease.

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

R N Jones, R. Jones, H. Sader, 1995, Diagnostic microbiology and infectious disease.

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

R. Jones, M. Erwin, M. Erwin, 1994, Diagnostic microbiology and infectious disease.

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.

Ronald N. Jones, P. Murray, R. Jones, 1993, Diagnostic microbiology and infectious disease.

In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Diagnostic microbiology and infectious disease.